Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2013; 5(11): 198-203
Published online Nov 15, 2013. doi: 10.4251/wjgo.v5.i11.198
Published online Nov 15, 2013. doi: 10.4251/wjgo.v5.i11.198
Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence
Osama E Rahma, Mauricio Burotto, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, United States
Luisa Matos Do Canto, Bassem R Haddad, John L Marshall, the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, United States
Alexandre A Germanos, Whitman College, Walla, WA 99362, United States
John L Marshall, the Ruesch Center for the Cure of GI Cancers, Georgetown University Medical Center, Washington, DC 20007, United States
Author contributions: Rahma OE, Haddad BR and Marshall JL designed the report; Do Canto LM, Germanos AA and Haddad BR performed the genetic analyses; Rahma OE and Burotto M collected the patient’s clinical data; Rahma OE, Haddad BR and Marshall JL analyzed the data and wrote the paper.
Supported by Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States
Correspondence to: John L Marshall, MD, Director, the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, United States. marshalj@georgetown.edu
Telephone: +1-202-4447064 Fax: +1-202-4441229
Received: August 16, 2013
Revised: October 9, 2013
Accepted: November 2, 2013
Published online: November 15, 2013
Processing time: 84 Days and 0.3 Hours
Revised: October 9, 2013
Accepted: November 2, 2013
Published online: November 15, 2013
Processing time: 84 Days and 0.3 Hours
Core Tip
Core tip: The role of genetic profiling in determining the risk of recurrence in colorectal cancer has been under serious investigation. This case report not only represents the longest rectal cancer disease-free interval in the literature, but also applies genetic analysis as a tool to confirm the similarity of the original and metastatic tumor and to predict the risk of recurrence.